Rallybio Q2 net loss $17.6M; Phase 1b RLYB212 shows platelet elimination; CFO to retire

Rallybio Corp

2022-Q2 EPS reported -$1.05

Net loss $17.6M ($0.57/share) vs $11.1M ($0.49) in Q2 2021 on higher R&D and G&A expenses.
Cash, equivalents and securities $147.4M as of June 30, 2022; runway into Q1 2024.
Phase 1b RLYB212 shows rapid elimination of HPA-1a positive platelets; protocol amended for broader dose range.
Phase 1 RLYB116 on track; initial single-dose data for 30 mg expected Q4 2022.
CFO Jeffrey Fryer to retire; external search for successor begun.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.